Back to search
FDAFDA · Food and drugs·Recall number D-0448-2017

Azelastine Hydrochloride Nasal Solution (Nasal Spray), 0.1% (137 mcg per spray), packaged in 30 mL bottles, Rx only, Distributed by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724, NDC 0054-0293-99

Published February 1, 2017 · Recall initiated: December 14, 2016

Summary

FDA records drug Class III recall D-0448-2017, published February 1, 2017 and initiated December 14, 2016. Recalling firm: Roxane Laboratories, Inc.; Status: Terminated; Reported quantity: 74,108 bottles; Lot: Lot # 659365A, Exp 3/31/2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective Delivery System: out of specification result for droplet size distribution at the d90 measurement testing during the 6 month time point..

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Roxane Laboratories, Inc.
Distributor
Nationwide and Puerto Rico.
Lot
Lot # 659365A, Exp 3/31/2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Azelastine Hydrochloride Nasal Solution (Nasal Spray), 0.1% (137 mcg per spray), packaged in 30 mL bottles, Rx only, Distributed by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724, NDC 0054-0293-99 recalled?

Yes. FDA published recall D-0448-2017 on February 1, 2017. Reported hazard: Defective Delivery System: out of specification result for droplet size distribution at the d90 measurement testing during the 6 month time point..

What should I do if I have this product?

Voluntary: Firm initiated · Letter